Breath Diagnostics, Inc. (BDx) uses a patented diagnostic test that quantifies cancer specific markers in exhaled breath to detect lung cancer (LC). This test, OneBreath, is easily administered, readily deployable, is non-invasive, and provides better accuracy than current radiographic technologies. OneBreath is ideally suited for application in three LC related indications: (1) as a primary screen for detection of LC; (2) to differentiate benign from malignant pulmonary nodules; and (3) to monitor for recurrence after surgical resection of LC.
In pre-clinical trials, OneBreath has demonstrated a sensitivity of 93.6% in detecting LC and a specificity of 77% in distinguishing benign from malignant pulmonary nodules. The breath cancer markers normalized after surgical removal of the tumor, thereby validating these markers as indicators of cancer.